Sanofi bets on its 'high-potential' pipeline; Ipsen preps muscle-spasm drug for review;

@FierceBiotech: With biotech stocks sizzling, drug developers are bringing home the bacon. Story | Follow @FierceBiotech

@JohnCFierce: AstraZeneca adds 550 jobs to the chopping block as profits shrivel. News | Follow @JohnCFierce

@DamianFierce Today in biotech IPOs: Revance, Eleven Biotherapeutics and Egalet raised a combined $196M in their debuts. Read | Follow @DamianFierce

@EmilyMFierce: Global cancer rates expected to hit 22 million new cases per year by 2030, according to WHO. Story via CBS News | Follow @EmilyMFierce

> Despite a stateside setback for Lemtrada, Sanofi ($SNY) is counting on its late-stage pipeline to deliver in 2014, deeming 9 of its 12 Phase III candidates as "high potential." Results (PDF)

> France's Ipsen is planning to file for approval for the muscle-spasm treatment Dysport Next Generation, citing a positive Phase III study. News

> FDA Commissioner Margaret Hamburg is on a voyage to India, meeting with drugmakers and regulators to address mounting quality concerns. Story

Medical Device News

@FierceMedDev: A judge said J&J wrongly eliminated thousands of key vaginal mesh docs. More | Follow @FierceMedDev

@MarkHFierce: Xerox is testing some really interesting patient monitoring tech. Yes, Xerox. Release | Follow @MarkHFierce

@MichaelGFierce: Check out FierceDrugDelivery's special report: The top drug delivery partnerships of 2013. Report | Follow @MichaelGFierce

@EmilyWFierce: GE sells off Breas Medical to PBM Capital. Release | Follow @EmilyWFierce

> Analysts: Rivals may seek to beat Smith & Nephew's $1.7B ArthroCare offer. Story

> St. Jude puts the Nanostim leadless pacemaker in its first U.S. patient. More

Pharma News

@FiercePharma: Pharma giants arm-twist U.S. government for IP action in India. Story | Follow @FiercePharma

@TracyStaton: AstraZeneca, on the other hand, saw Q4/full year 'in line with our expectations,' which means generics are still hitting hard. | Follow @TracyStaton

@EricPFierce: The FDA prescription for fighting counterfeit drugs includes targeting the docs who buy them. More | Follow @EricPFierce

> Generics pull AZ sales back again, but CEO promises a quicker bounce-back. Story

> AstraZeneca steps up its global restructuring with 550 new job cuts. News

> After tougher-than-expected 2013, Sanofi anticipates patent-cliff freedom. More

> Pharma giants arm-twist U.S. government for IP action in India. Piece

Pharma Manufacturing News

> FDA Commissioner Hamburg heads for India to talk about quality manufacturing. News

> As Ranbaxy's plant problems mount, so do its losses. More

> BMS plots major job cuts at plants in France. Story

> AbbVie picks Singapore for a $320M production facility. Article

> 7 Ohio docs pony up $2.6M for buying foreign-made cancer drugs. Piece

> Teva, which has been tightening its supply chain, turns in a surprising financial report. Item

Vaccines News

> GSK is refusing to write off its cancer vaccine despite last year's PhIII flop. Article

> Circassia to test U.K. investors' appetite for risk with a $285M IPO. More

> Buzz: Novartis mulls selling its vaccine unit as swap deal with Merck stalls. Story

> Study: Merck's and GSK's HPV vaccines don't encourage risky sex. Piece

> CDC finds rare cases of nurses injecting GSK's and Merck's oral rotavirus vaccines. News

NIH leaders view HIV vaccine as essential to ending AIDS pandemic. Item

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.